<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the successes in expressing NVCP VLPs and a variety of other subunit vaccines in plants and the recent improvement of vaccine production levels by transient expression systems, no plant-derived vaccine has been licensed yet for human use. This lack of commercial success lies in several technical and regulatory barriers that remain to be overcome. These challenges include the lack of scalable downstream processing procedures, the uncertainty of regulatory compliance of production processes, and the lack of demonstration to date of plant-derived vaccines that meet the required standards of regulatory agencies in identity, purity, potency, and safety [
 <xref ref-type="bibr" rid="CR0008123">123</xref>, 
 <xref ref-type="bibr" rid="CR0008124">124</xref>, 
 <xref ref-type="bibr" rid="CR0008127">127</xref>].
</p>
